SynthesisBasic & clinical pharmacology & toxicology2014
Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals.
Synthesis in Basic & clinical pharmacology & toxicology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.Clinical pharmacology and therapeutics · 2023Guideline
- Emotional Blunting in Depression in the PREDDICT Clinical Trial: Inflammation-Stratified Augmentation of Vortioxetine With Celecoxib.The international journal of neuropsychopharmacology · 2024Trial
- Clinical benefits and bioequivalence of vortioxetine oral drop solution versus oral tablets.Journal of psychopharmacology (Oxford, England) · 2024Trial
- Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study.International clinical psychopharmacology · 2020Trial
- Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study.International clinical psychopharmacology · 2019Trial
- Trial
- Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single- and Multiple-Dose Administration in Healthy Japanese Adults.Clinical pharmacology in drug development · 2018Trial
- Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients.Journal of child and adolescent psychopharmacology · 2017Trial
- Bioequivalence of a Generic Vortioxetine 20 mg Tablet in Healthy Mexican Volunteers Under Fasting Conditions.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Time to efficacious steady state plasma concentrations with slow titration of Vortioxetine drops versus oral tablets: a Pharmacokinetic model.Annals of general psychiatry · 2025Article
- Effects of Vortioxetine on Sleep Architecture of Adolescents with Major Depressive Disorder.Clocks & sleep · 2023Article
- Does ethnicity impact CYP2D6 genotype-phenotype relationships?Clinical and translational science · 2023Article
- Therapeutic Potential and Limitation of Serotonin Type 7 Receptor Modulation.International journal of molecular sciences · 2023Review
- Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles Through Population Pharmacokinetic Analysis of Vortioxetine.Clinical pharmacology and therapeutics · 2021Article
- Pharmacokinetics and Safety of Vortioxetine in the Chinese Population.Advances in therapy · 2019Article
- Vortioxetine: Clinical Pharmacokinetics and Drug Interactions.Clinical pharmacokinetics · 2018Review
- The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.Journal of psychopharmacology (Oxford, England) · 2016Article
- A review of significant pharmacokinetic drug interactions with antidepressants and their management.The mental health clinician · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective was to describe the pharmacokinetics of vortioxetine and evaluate the effect of intrinsic and extrinsic factors in the healthy population. Data from 26 clinical pharmacology studies were pooled. A total of 21,758 vortioxetine quantifiable plasma concentrations were collected from 887 subjects with corresponding demography. The doses ranged from 2.5 to 75 mg (single dose) and 2.5-60 mg (multiple QD doses). The pharmacokinetics of vortioxetine was best characterised by a two-compartment model with first-order absorption, lag-time and linear elimination, with interindividual error terms for absorption rate constant, oral clearance and central volume of distribution. The population mean was 32.7 L/hr for oral clearance and 1.97∙10(3) L for the central volume of distribution. The average elimination half-life was 65.8 hr. CYP2D6 inferred metabolic status (ultra, extensive, intermediate or poor metabolisers) and age on oral clearance and height on central volume of distribution were identified as statistically significant covariate-parameter relationships. For CYP2D6 poor metabolisers, CL/F was approximately 50% to that seen in CYP2D6 extensive metabolisers. The impact of height on V2/F and age on CL/F was low and not considered to be clinically relevant. The final model was found to be reliable, stable and predictive. A reliable, stable and predictive pharmacokinetic model was developed to characterise pharmacokinetics of vortioxetine in the healthy population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.